PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA
Clinical trials for PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA trials appear
Sign up with your email to follow new studies for PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat ovarian cancer: drug combo trial launches
Disease control Recruiting nowThis study tests a combination of two drugs, vismodegib and atezolizumab, in people with ovarian, fallopian tube, or peritoneal cancer that no longer responds to platinum-based chemotherapy. The goal is to see if this treatment can shrink tumors or slow the disease. About 48 part…
Matched conditions: PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: Ronald Buckanovich • Aim: Disease control
Last updated May 17, 2026 00:46 UTC
-
New hope for Hard-to-Treat ovarian cancer: PLX038 trial launches
Disease control Recruiting nowThis study tests a drug called PLX038 in people with ovarian, fallopian tube, or peritoneal cancer that has spread and no longer responds to platinum chemotherapy. The goal is to see if PLX038 can shrink tumors. About 43 adults with advanced cancer will receive the drug, and rese…
Matched conditions: PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 17, 2026 00:44 UTC
-
Supercharged immune cells take on Hard-to-Treat ovarian cancer
Disease control Recruiting nowThis early-stage study tests a new treatment for ovarian cancer that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells (T cells) that are trained in a lab to recognize and attack a protein called MUC1 found on cancer cells. The ma…
Matched conditions: PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New hope for Hard-to-Treat ovarian cancer: experimental drug lorigerlimab enters phase 2 trial
Disease control Recruiting nowThis study tests an experimental drug called lorigerlimab in about 60 people with advanced ovarian or other gynecologic cancers that no longer respond to standard chemotherapy. Participants receive the drug by IV every 3 weeks. The goal is to see if the drug can shrink tumors and…
Matched conditions: PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: MacroGenics • Aim: Disease control
Last updated May 11, 2026 20:47 UTC